期刊文献+

坡那替尼的合成

Synthesis of Ponatinib
原文传递
导出
摘要 2-甲基-5-硝基三氟甲苯(2)经溴代、取代、还原、成酰胺得到关键中间体3-碘-4-甲基-N-[4-[(4-甲基-1-哌嗪)甲基]-3-(三氟甲基)苯基]苯甲酰胺(6)。另外,3-溴咪唑并[1,2-b]哒嗪(7)经Sonogashira反应和脱保护得到3-乙炔咪唑并[1,2-b]哒嗪(9)。6与9经Sonogashira反应制得BCR-ABL酪氨酸激酶抑制剂坡那替尼,总收率约70%(以2计)。 N- [3- (trifluoromethyl) -4- [ (4-methylpiperazin- 1-yl) methyll phenyl] -3-iodo-4-methylbenzamide (6) was prepared from 2-methyl-5-nitro-trifluoromethylbenzene (2) via bromination, substitution, reduction and amidation. Meanwhile, 3-ethynylimidazo [ 1,2-b] pyridazine (9) was produced from 3-bromoimidazo [ 1,2-b] pyridazine (7) via Sonogashira reaction and deprotection. Finally, ponatinib was synthesized from 6 and 9 by Sonogashira reaction. The overall yield was about 70 % based on 2.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第9期812-815,共4页 Chinese Journal of Pharmaceuticals
关键词 BCR-ABL T315I 酪氨酸激酶抑制剂 坡那替尼 合成 BCR-ABL T3151 tyrosine kinase inhibitor ponatinib synthesis
  • 相关文献

参考文献7

  • 1Full prescribing information for Iclusig[EB/OL].[2013-12-23].http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203469s007s0081bl.pdf.
  • 2O'Hare T,Shakespeare WC,Zhu X,et al.AP24534,a panBCR-ABL inhibitor for chronic myeloid leukemia,potently inhibits the T315I mutant and overcomes mutation-based resistance[J].Cancer Cell,2009,16:401-412.
  • 3Huang W,River V,Clackson T,et al.Methods and compositions for treating cancer:WO,2011053938[P].2011-05-05.
  • 4Chinchilla R,Nájera C.The Sonogashira reaction:a booming methodology in synthetic organic chemistry[J].Chem Rev,2007,107 (3):874-922.
  • 5谢宁,李艳阳,赵砚瑾,李庶心.抗肿瘤药ponatinib的合成[J].中国新药杂志,2013,22(22):2688-2691. 被引量:5
  • 6Huang WS,Metcalf CA,Sundaramoorthi R,et al.Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)-phenyl}benzamide (AP24534),a potent,orally active paninhibitor of breakpoint cluster region-abelson (BCR-ABL)kinase including the T315I gatekeeper mutant[J].J Med Chem,2010,53 (12):4701-4719.
  • 7田坤,岳洪亮,周长岭,戴娟,陈海霞,刘艳,徐浩.泊那替尼的合成[J].广东化工,2013,40(12):24-25. 被引量:1

二级参考文献13

  • 1张连第,郭成.咪唑并[1,2-b]哒嗪的合成研究[J].江苏化工,2005,33(4):48-50. 被引量:6
  • 2Zhou T. Structural Mechanism of the Pan - BCR - ABL Inhibitor Ponatinib (AP24534): Lessons for overcoming Kinase Inhibitor Resistance[J]. Chemical biology & drug design, 2011, 77(1): 1-11.
  • 3O'Hare T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance[J]. Cancer Cell, 2009. 16(5): 401-412.
  • 4Huang W S. Discovery of 3-[2-(imidazo [1, 2-b] pyridazin-3-yl) ethynyl]-4-methyl-N- {4-[(4-methylpiperazin- 1 -yl) methyl]-3 -(trifluoromethyl) phenyl} benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant[J]. Journal of medicinal chemistry, 2010. 53(12): 4701-4719.
  • 5Chinchilla R , Naijera C . Recent advances in Sonogashira reactions[J]. Chem. Soc. Rev., 2011, 40(10): 5084-5121.
  • 6HUANG WS,METCALF CA,SUNDARAMOORTHI R,et al.Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)-methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534),a potent,orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant[J].J Med Chem,2010,53:4701-4719.
  • 7ZUPAN M,POLLAK A.Fluorination with xenon difluoride.Reaction with halogenated hydrocarbons[J].J Fluor Chem,1976,8(3):275-278.
  • 8ZOU D,HUANG WS,TOMAS R,et al.Bicyclic heteroaryl compounds:WO,2007075869 A[P].2007-07-05.
  • 9朱自力.选择性乙酰辅酶A羧化酶2抑制剂(ACC2)苯氧基噻唑炔衍生物的合成改进[J].广东化工,2009,36(4):23-24. 被引量:1
  • 10李婉贞,薛晓文.针对Abl-T315I突变的Bcr-Abl蛋白激酶抑制剂的研究进展[J].药学与临床研究,2012,20(4):326-329. 被引量:2

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部